Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Triple Negative Breast Neoplasms 1Smoldering Multiple Myeloma 1Pancreatic Neoplasms 1Multiple Myeloma 1Breast Neoplasms 1Breast Diseases 1

Interventions

Fulvestrant 63Letrozole 53Paclitaxel 50Trastuzumab 42pembrolizumab 40ribociclib 38Specimen Handling 37palbociclib 36Capecitabine 35Carboplatin 33Anastrozole 33Tamoxifen 32exemestane 29pertuzumab 28abemaciclib 28Magnetic Resonance Spectroscopy 26Cyclophosphamide 26trastuzumab deruxtecan 25Surveys and Questionnaires 22Biopsy 19olaparib 18Standard of Care 18Radiotherapy 18Docetaxel 16Blood Specimen Collection 16elacestrant 14Taxes 14Mastectomy, Segmental 14eribulin 13Methods 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Neoplasms × Leflunomide × 90 days × Clear all
NCT03709446 2026-03-19

Leflunomide in Previously Treated Metastatic Triple Negative Cancers

Icahn School of Medicine at Mount Sinai

Phase 1/2 Completed
17 enrolled
Breast

Breast Diseases, Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡